Barrington Research Initiates Coverage On Viemed Healthcare with Outperform Rating, Announces Price Target of $14
Barrington Research initiates coverage on Viemed Healthcare (NASDAQ:VMD) with a Outperform rating and announces Price Target of $14.
Stocks · News reference
Viemed Healthcare Q2 EPS $0.07 Misses $0.12 Estimate, Sales $78.097M Miss $78.100M Estimate
Viemed Healthcare (NASDAQ:VMD) reported quarterly earnings of $0.07 per share which missed the analyst consensus estimate of $0.12 by 41.67 percent. This is a 12.5 percent decrease over earnings of $0.08 per share from
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — VIEMED HEALTHCARE, INC. (VMD)
Filed: 2026-08-20 AccNo: 0001729149-26-000048 Size: 4 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Viemed Healthcare Raises FY2026 Sales Guidance from $312.000M-$320.000M to $314.000M-$320.000M vs $317.300M Est
Viemed Healthcare (NASDAQ:VMD) raises FY2026 sales outlook from $312.000 million-$320.000 million to $314.000 million-$320.000 million vs $317.300 million estimate.